ArticleACS pharmacology & translational science2025
Cardioprotective Potential of ApoE-Derived Peptide (ApoEFrag) in Myocardial Infarction in Rats: A Mechanistic Study.
Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) are the leading cause of death among non-communicable diseases globally. Myocardial infarction (MI) is one of the most significant CVDs resulting from acute or chronic myocardial ischemia, which can lead to irreversible damage. Despite the substantial burden posed by these conditions, specific treatments remain limited to symptomatic management. ApoEFrag has been shown to be protective in the CNS. However, the cardioprotective potential of ApoE-mimetic has not been investigated. Thus, this study investigates the cardioprotective potential of ApoEFrag, a novel ApoE-mimetic peptide, in an acute MI model in rats. MI was induced in rats through two doses of isoproterenol (100 mg/kg via subcutaneous injection) administered 24 h apart. ApoEFrag was given at doses of 0.5 and 1 mg/kg to ISO-treated rats. Following treatment, we measured electrocardiogram (ECG) changes and arterial and ventricular pressure functions using the PV-loop system. Plasma and heart samples were collected for biochemical assessments, including plasma injury markers, hypertrophic index parameters, inflammatory markers, gene/protein expression analysis, and histopathological studies. ISO-induced MI resulted in alterations in ECG patterns, ventricular dysfunction, increased fibrosis, and elevated hypertrophic index parameters. Additionally, ISO administration led to increased inflammatory markers and oxidative stress levels, which were reversed by the ApoEFrag treatment. Furthermore, ApoEFrag significantly ameliorated cardiac injury, inflammation, hypertrophic index parameters, ECG alterations, ventricular dysfunction, and cardiac fibrosis in ISO-induced MI models. Notably, ApoEFrag also improved mitochondrial health. This study suggests that ApoEFrag has significant cardioprotective potential in an acute myocardial infarction model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.